Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).
acute myeloid leukemia
azacitidine
elderly
post-remission therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Apr 2023
24 Apr 2023
Historique:
received:
01
03
2023
revised:
11
04
2023
accepted:
21
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
This phase-3 randomized multicenter trial evaluated the efficacy of subcutaneous azacitidine (AZA) post-remission therapy vs. best supportive care (BSC) in elderly acute myeloid leukemia (AML) patients. The primary endpoint was the difference in disease-free survival (DFS) from complete remission (CR) to relapse/death. Patients with newly diagnosed AML aged ≥61 years received two courses of induction chemotherapy ("3+7" daunorubicin and cytarabine) followed by consolidation (cytarabine). At CR, 54 patients were randomized (1:1) to receive BSC (N = 27) or AZA (N = 27) at a dose of 50 mg/m
Identifiants
pubmed: 37173908
pii: cancers15092441
doi: 10.3390/cancers15092441
pmc: PMC10177242
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Haematol. 2010 Aug;150(3):293-302
pubmed: 20497178
Hematol Oncol Clin North Am. 2020 Aug;34(4):689-699
pubmed: 32586574
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Blood Adv. 2022 Mar 8;6(5):1619-1622
pubmed: 34607349
Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9
pubmed: 25460355
Front Oncol. 2021 Feb 02;10:619085
pubmed: 33604298
Leukemia. 2005 Aug;19(8):1479-82
pubmed: 15973451
Am J Hematol. 2019 Nov;94(11):1254-1265
pubmed: 31429099
Aging (Albany NY). 2020 Dec 20;12(24):24734-24777
pubmed: 33349623
Am J Hematol. 2019 Jul;94(7):803-811
pubmed: 30945331
Ann Hematol. 2014 Dec;93(12):2081-2
pubmed: 24863693
Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):236-250
pubmed: 34758945
Leukemia. 2017 Jan;31(1):34-39
pubmed: 27624549
Expert Rev Hematol. 2010 Aug;3(4):429-41
pubmed: 21083034
Blood. 2016 Aug 11;128(6):763-73
pubmed: 27354720
JAMA. 2009 Jun 10;301(22):2349-61
pubmed: 19509382
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Stem Cells Transl Med. 2022 May 27;11(5):461-477
pubmed: 35438781
Leuk Lymphoma. 2018 Feb;59(2):274-287
pubmed: 28573892
Leuk Res. 2015 Mar;39(3):296-306
pubmed: 25601157
Blood. 2017 Aug 31;130(9):1156-1164
pubmed: 28674027
Blood Adv. 2022 Mar 8;6(5):1623-1627
pubmed: 34607346
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Blood Rev. 2021 Sep;49:100829
pubmed: 33832807
Blood. 2019 Mar 28;133(13):1457-1464
pubmed: 30630862
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Hematol Oncol. 2014 Mar;32(1):1-9
pubmed: 23512815
Cancers (Basel). 2022 Oct 06;14(19):
pubmed: 36230820
Haematologica. 2011 May;96(5):696-702
pubmed: 21330327
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
JAMA Oncol. 2018 Oct 1;4(10):1389-1397
pubmed: 30098165
Front Med (Lausanne). 2022 Feb 15;9:801632
pubmed: 35242779
Blood. 2022 Apr 7;139(14):2145-2155
pubmed: 34995344
Cancer. 2007 Jul 1;110(1):196-202
pubmed: 17546575
N Engl J Med. 2020 Dec 24;383(26):2526-2537
pubmed: 33369355
Am J Hematol. 2015 Sep;90(9):796-9
pubmed: 26089240
Blood Adv. 2018 Jul 10;2(13):1645-1650
pubmed: 29991495
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Leuk Res. 2021 Dec;111:106736
pubmed: 34773794